Ex-Sepracor chief to lead startup biotech

Share this article:

Mark Iwicki, previously president and CEO of Sepracor, has signed on as chief executive officer with oncology-focused pipeline biopharma Blend Therapeutics. This news comes in tandem with the announcement that Blend has secured $16 million in Series B financing. Blend received $2.8 million last year when the company was first established.

The Massachusetts-based firm hopes to deliver a safer platinum-based chemotherapy through a delivery vehicle with nanoparticles.

In an interview with Xconomy, Iwicki said the funds will allow the company to operate through drug development for another two years, during which time Blend hopes to file an investigational drug application with the FDA.

Iwicki joined Sepracor in 2007 as EVP, chief commercial officer. Two years later, when Sepracor was acquired by Dainippon Sumitomo Pharmaceuticals and became Sunovion, Iwicki took the reins as chief executive officer.

The acquisition was motivated by Dainippon Sumitomo's desire to bring schizophrenia treatment Latuda to market by way of Sepracor's existing CNS marketing and sales infrastructure.  Latuda won approval in October 2010 amidst a crowded antipsychotic therapeutic category.

In our October, 2006 issue MM&M listed Iwicki as one of our '15 on the rise.' One of his nominators aptly noted, “He is going to run a drug company one day.”
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...